Your browser is no longer supported. Please, upgrade your browser.
Settings
ZFGN Zafgen, Inc. daily Stock Chart
ZFGN [NASD]
Zafgen, Inc.
Index- P/E- EPS (ttm)-1.95 Insider Own0.80% Shs Outstand27.88M Perf Week-7.58%
Market Cap105.39M Forward P/E- EPS next Y-1.91 Insider Trans9.85% Shs Float26.04M Perf Month-24.10%
Income-53.20M PEG- EPS next Q-0.55 Inst Own71.70% Short Float3.29% Perf Quarter-6.44%
Sales- P/S- EPS this Y23.60% Inst Trans3.25% Short Ratio4.11 Perf Half Y7.08%
Book/sh4.05 P/B0.93 EPS next Y20.10% ROA-38.80% Target Price6.50 Perf Year-44.66%
Cash/sh4.19 P/C0.90 EPS next 5Y- ROE-42.10% 52W Range2.89 - 7.73 Perf YTD18.87%
Dividend- P/FCF- EPS past 5Y-27.30% ROI- 52W High-51.10% Beta-
Dividend %- Quick Ratio13.80 Sales past 5Y- Gross Margin- 52W Low30.80% ATR0.21
Employees32 Current Ratio13.80 Sales Q/Q- Oper. Margin- RSI (14)25.40 Volatility3.74% 4.82%
OptionableYes Debt/Eq0.03 EPS Q/Q26.90% Profit Margin- Rel Volume0.87 Prev Close3.85
ShortableYes LT Debt/Eq0.00 EarningsMay 09 Payout- Avg Volume208.12K Price3.78
Recom2.80 SMA20-14.58% SMA50-18.50% SMA200-0.92% Volume181,875 Change-1.82%
Apr-20-17Initiated ROTH Capital Buy $9
Jan-06-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jul-20-16Downgrade FBR Capital Outperform → Mkt Perform $20 → $5
Mar-10-16Reiterated RBC Capital Mkts Outperform $21 → $19
Jan-21-16Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $21
Jan-21-16Upgrade FBR Capital Mkt Perform → Outperform $9 → $20
Dec-03-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
Dec-03-15Downgrade Leerink Partners Outperform → Mkt Perform
Dec-02-15Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $7
Nov-13-15Reiterated Canaccord Genuity Buy $53 → $30
Oct-19-15Reiterated RBC Capital Mkts Outperform $46 → $20
Oct-19-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-16-15Downgrade FBR Capital Outperform → Mkt Perform $48 → $16
Oct-15-15Reiterated RBC Capital Mkts Outperform $58 → $46
Oct-15-15Reiterated FBR Capital Outperform $60 → $48
Jun-17-15Initiated Sun Trust Rbsn Humphrey Buy $47
May-13-15Reiterated Canaccord Genuity Buy $58 → $53
Jan-23-15Initiated RBC Capital Mkts Outperform $53
Aug-13-14Initiated Canaccord Genuity Buy $36
May-09-17 06:30PM  Zafgen reports 1Q loss Associated Press
04:05PM  Zafgen Reports First Quarter 2017 Financial Results GlobeNewswire
May-04-17 04:05PM  Zafgen Rebounds With a Safer Obesity Drug Targeting Diabetics TheStreet.com
04:05PM  Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor GlobeNewswire
May-02-17 07:55PM  Edited Transcript of ZFGN earnings conference call or presentation 9-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
04:42PM  Edited Transcript of ZFGN earnings conference call or presentation 10-May-16 8:30pm GMT Thomson Reuters StreetEvents
Mar-16-17 01:04PM  ZAFGEN, INC. Financials
Mar-10-17 04:10PM  ZAFGEN, INC. Files SEC form 10-K, Annual Report +12.66%
Mar-09-17 06:45PM  Zafgen reports 4Q loss Associated Press
04:12PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-02-17 04:05PM  Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 04:05PM  Zafgen to Present at Upcoming Investor Conferences GlobeNewswire
Feb-09-17 04:05PM  Zafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Jan-06-17 07:17AM  Zafgen upgraded by JMP Securities +24.78%
Dec-12-16 11:44PM  How Zafgen Inc (ZFGN) Stacks Up Against Its Peers Insider Monkey
11:44PM  How Zafgen Inc (ZFGN) Stacks Up Against Its Peers at Insider Monkey
Dec-01-16 08:47AM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
08:47AM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-09-16 05:57PM  Zafgen reports 3Q loss +8.20%
04:15PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports Third Quarter 2016 Financial Results GlobeNewswire
Sep-20-16 12:17PM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016 Capital Cube +6.37%
12:17PM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016
07:00AM  Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061 GlobeNewswire
Aug-05-16 06:07AM  ZAFGEN, INC. Files SEC form 10-Q, Quarterly Report +5.57%
Aug-04-16 06:43PM  Zafgen reports 2Q loss
04:13PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-03-16 05:00PM  Zafgen to Present at Canaccord Genuitys 36th Annual Growth Conference GlobeNewswire
09:30AM  Zacks.com featured highlights: Danaos, Telecom Italia, Fibria Celulose, Goodyear Tire & Rubber and Zafgen Zacks
Jul-29-16 09:53AM  Zafgen (ZFGN) Is in Oversold Territory: What's Next?
Jul-21-16 04:04PM  Biotech Firm Zafgen in Thursdays 52-Week Low Club at 24/7 Wall St. -7.72%
09:30AM  The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
Jul-20-16 04:04PM  2 Staggering Biotechs Join Wednesdays 52-Week Low Club at 24/7 Wall St. -52.00%
03:50PM  Why Valeant, Progenics, Ryerson, Zafgen and TerraForm Are On The Move Today at Insider Monkey
03:36PM  Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
10:45AM  Why Zafgen (ZFGN) Stock Is Tanking Today
09:44AM  Zafgen Halts Development of Beloranib, to Cut Jobs by ~34%
Jul-19-16 05:35PM  Zafgen shares drop more than 40% as drug focus shifted at MarketWatch
05:22PM  ZAFGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex
04:47PM  Zafgen to scrap obesity drug, cut jobs
04:05PM  Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061 GlobeNewswire
Jul-01-16 04:32PM  ZAFGEN, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-13-16 05:45PM  Zafgen (ZFGN) Presents Favorable New Data on Beloranib
09:36AM  Zafgen up 6% after weight loss drug has positive late-stage trial results at MarketWatch
Jun-11-16 11:00AM  Zafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions GlobeNewswire
Jun-06-16 02:28PM  Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
May-11-16 11:20AM  Hopes rise for FDA approval of Zafgens fat-busting drug among analysts, investors at bizjournals.com
May-10-16 06:14PM  Zafgen reports 1Q loss
04:30PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports First Quarter 2016 Financial Results GlobeNewswire
May-03-16 04:05PM  Zafgen to Host Conference Call to Discuss First Quarter 2016 Financial Results GlobeNewswire
Apr-06-16 01:53PM  Edited Transcript of ZFGN earnings conference call or presentation 9-Mar-16 9:30pm GMT
Apr-04-16 02:47PM  Why These Five Stocks Are Trending on Monday at Insider Monkey +8.66%
11:42AM  Penny Stocks To Buy: Traders Are Considering Stocks On This List, Monday 4/4/2016 Accesswire
10:21AM  Zafgen (ZFGN) Stock Surges on Positive Obesity Drug Trial at TheStreet
08:42AM  Biotech Firm Receives Key Patent Notice Accesswire
Apr-03-16 01:15PM  Zafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016 GlobeNewswire
Mar-28-16 04:22PM  Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016 at noodls
04:05PM  Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016 GlobeNewswire
Mar-24-16 07:15AM  Why investors arent really buying Kerrisdales short attack on Sage Therapeutics at bizjournals.com
Mar-15-16 04:15PM  ZAFGEN, INC. Files SEC form 10-K, Annual Report
Mar-10-16 03:16PM  Zafgen (ZFGN) Stock Sinks on Q4 Loss at TheStreet -9.78%
Mar-09-16 04:55PM  Zafgen reports 4Q loss
04:20PM  ZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Zafgen Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Mar-08-16 05:02PM  ZAFGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State -8.20%
07:00AM  Zafgen Adds Thomas O. Daniel, M.D. to Its Board of Directors GlobeNewswire
Mar-02-16 04:00PM  Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire +9.19%
Mar-01-16 07:00AM  Zafgen to Present at the Cowen & Company 36th Annual Health Care Conference GlobeNewswire
Feb-29-16 07:00AM  Zafgen Joins NORD in Raising Awareness of Rare Disease Day GlobeNewswire -8.21%
Feb-20-16 10:15AM  The Top 4 Biopharma Movers of the Past Week at 24/7 Wall St.
Feb-19-16 04:05PM  Thromboembolic Risks Linger For Zafgen's Beloranib, Says SunTrust
03:20PM  Zafgen Up, Beloranib Hits Phase IIb Primary Efficacy Endpoint
Feb-18-16 04:25PM  Die Hard starts winning again
12:05PM  Zafgen's drug may help one of the leading causes of death, but safety issues remain at bizjournals.com
08:50AM  Zafgen Soars on Positive Phase 2 Results at 24/7 Wall St.
08:48AM  Here's Why Zafgen Gained 20% Thursday Morning
07:01AM  ZAFGEN, INC. Files SEC form 8-K, Other Events
06:48AM  Zafgen's obesity drug succeeds in mid-stage trial Reuters
06:30AM  Zafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint GlobeNewswire
Feb-17-16 11:52AM  This firm is now one of just two Mass. biotechs trading up this year at bizjournals.com
Feb-16-16 04:05PM  Zafgen to Participate in Upcoming Investor Conferences GlobeNewswire +10.20%
Feb-12-16 02:07PM  Billionaire Singer Lifts Stake in Cabelas Inc. (CAB), Deerfield Bets on Beloranib, Plus Two Other Moves at Insider Monkey
Feb-11-16 10:13AM  5 Stocks Under $10 Set to Soar at TheStreet
Feb-02-16 07:00AM  Zafgen to Present at Upcoming Investor Conferences GlobeNewswire
Feb-01-16 08:00AM  Biotech Sector Report; Potential Rebound for These Four Biotech Securities Accesswire
Jan-25-16 01:31PM  Some cheap biotech stocks that could be buyout targets, RBC says at MarketWatch -10.52%
12:51PM  Why Zafgen (ZFGN) Stock Is Falling Today at TheStreet
12:25PM  Why Zafgen Inc's Stock Is in the Red Today at Motley Fool
11:02AM  Zafgen stock tumbles after hedge fund reveals short position Reuters
09:36AM  Kerrisdale Short Zafgen, Says Beloranib Has 'No Reasonable Chance' Of FDA Approval And Recent Bullishness Is 'Misplaced'
Jan-21-16 03:30PM  Zafgen Soars on Positive Phase III Efficacy Data on Beloranib -9.26%
12:09PM  Zafgen (ZFGN) Stock Upgraded at RBC Capital at TheStreet
11:51AM  Zafgen Doubles: What Do The Experts Think?
08:55AM  Top Analyst Upgrades and Downgrades: GE, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell and Many More at 24/7 Wall St.
Jan-20-16 05:29PM  ZAFGEN, INC. Files SEC form 8-K, Other Events +78.65%
03:42PM  What is Happening to These Stocks on Wednesday? at Insider Monkey
03:00PM  Zafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Results at TheStreet
Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company's lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hughes Thomas E.President and CEOMay 11Option Exercise0.8093,21174,673157,371May 15 08:22 PM
KIM DENNIS DChief Medical OfficerMay 11Buy4.409,80043,12011,443May 11 06:59 PM
KIM DENNIS DChief Medical OfficerMay 10Buy4.402008801,643May 11 06:59 PM
Heller Frances KDirectorDec 19Buy3.2310,00032,29030,000Dec 20 05:02 PM
Heller Frances KDirectorNov 15Buy3.5410,00035,43420,000Nov 17 05:00 PM